Diversity + Inclusion In Clinical Trials

NEMA Research supports diversity, equity, and inclusion in Clinical Trials. NEMA has deep-rooted diversity, equity, and inclusion goals and programs to support anyone and everyone. NEMA Research focuses on different ages, genders, and racial, cultural and ethnic backgrounds because different people may experience the same condition differently, and that medications can behave differently in various populations. Diverse trial participation gives sponsors better insight into how the new drug product is likely to perform in a broader range of patients in the “real world.” Ultimately, that’s good for all patients and for a clinical trial. Including diverse groups in clinical trials also increases access to cutting-edge treatments for groups that traditionally have been underserved. Recognizing the value of including diverse populations in clinical research, both the US Food and Drug Administration (FDA) and the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) have issued multiple guidance documents on the subject. Change needs to start early in the drug development process. From age and gender to geographic ancestry and psychosocial stress, many factors affect treatment response and health outcomes.